Category: Endoscopic / Arthroscopic
Endoscopic / Arthroscopic
Xlumena says it closed a $25 million Series C round as it pursues FDA clearance for its Axios stent and delivery system.
Xlumena said it closed a $25 million Series C round it plans to use to expand its commercial footprint and win FDA clearance for its Axios stent and delivery system.
Cantel Medical acquires Israel-based Jet Prep Ltd. and its FDA-cleared and CE-Marked Flushing Device.
Cantel Medical (NYSE:CMN) today announced the acquisition of Jet Prep Ltd, an endoscopy device company based in Herzliya, Israel.
Jet Prep is the developer of the Jet Prep Flushing Device, an endoscopic tool used for washing mucosal tissue in the gastrointestinal tract which already has regulatory clearances for the U.S. and E.U. markets.
Endoscopic surgical devices maker Medigus Ltd. touts a $7 million raise from investors in Israel and the U.S.
Israel-based Medigus closed a $7 million funding round, raised through sales of shares and options at about 20¢ apiece (NIS 0.72).
The sale, joined by investors in the U.S. as well as Israel, represents about 21% of the company's voting power combined with about 17.3 million 3-year options, according to a press release.
California weight-loss surgery systems maker USGI Medical lands FDA approval to launch what may be the largest pivotal study of its kind for an endoscopic weight-loss procedure.
USGI Medical will enroll up to 350 patients in an FDA-approved clinical trial of the g-Cath EZ suture anchor delivery catheter, an incision-free bariatric surgery technology that has already been used on more than 2,000 patients, mostly in Europe.
Sanovas raises a $6.5 million Series A1 round for its Vas Zeppelin pulmonary device and MicroCam plug-and-play endoscopic imaging system.
Sanovas raised $6.5 million in a Series A1 round co-founder & CEO Larry Gerrans told MassDevice.com will go toward commercializing its Vas Zeppelin pulmonary device.
Sausalito, Calif.-based Sanovas closed a Series A round last summer consisting entirely of friends and family, Gerrans told us.
Vision-Sciences says a 3-month study of its EndoSheath device in a field hospital in Afghanistan delivered positive results.
Vision-Sciences (NSDQ:VSCI) said a small study of its EndoSheath bronchoscopy device in a field hospital in Afghanistan found that the single-use device reduces the risk of cross-contamination and avoids the need for complex sterilization procedures for bronchoscopes.
SafeStitch Medical says it's agreed to a merger with private equity-backed TransEnterix and plans to issue a $30 million private placement.
SafeStitch Medical (OTC:SFES) and TransEnterix are set to merge next quarter in a deal that includes a private placement worth about $30 million.